Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma.
Publication
, Conference
Mowery, YM; Niedzwiecki, D; Choe, JH; Kirsch, DG; Brizel, DM
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Mowery, Y. M., Niedzwiecki, D., Choe, J. H., Kirsch, D. G., & Brizel, D. M. (2022). Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Mowery, Yvonne Marie, Donna Niedzwiecki, Jennifer Hsing Choe, David G. Kirsch, and David M. Brizel. “Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Mowery YM, Niedzwiecki D, Choe JH, Kirsch DG, Brizel DM. Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.
Mowery, Yvonne Marie, et al. “Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.
Mowery YM, Niedzwiecki D, Choe JH, Kirsch DG, Brizel DM. Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma. JOURNAL OF CLINICAL ONCOLOGY. 2022.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences